Skip to main content
. 2022 Aug 5;16:1999–2007. doi: 10.2147/PPA.S370323

Table 3.

Baseline and Final Values of Clinical Characteristics

Glucose, mg/dL HbA1c, % (mmol/mol)
Baseline Final p Baseline Final p
Control group (n=43) 157.3±47.6 157.2±38.2 0.194 8.86 (73) ±1.80 8.80 (73) ±1.34 0.436
Intervention group (n=46) 148.5±28.7 139.2±15.6 <0.001 9.07 (73) ±1.76 7.6 (60) ±0.96 <0.001
SBP, mmHg DBP, mmHg
Baseline Final p Baseline Final p
Control group (n=43) 140.95±13.7 141.14±13.1 0.782 92.26±6.12 92.91±6.25 0.425
Intervention group (n=46) 139.9±10.14 130.15±11.8 <0.001 92.83±6.01 87±3.83 <0.001
Cholesterol, mg/dL Triglycerides, mg/dL
Baseline Final p Baseline Final p
Control group (n=43) 171.62±30.5 169.2±27.4 0.007 162.95±45.9 158.5±39.7 0.049
Intervention group (n=46) 181.4±27.7 170.1±26.4 <0.001 167.74±32.3 153.7±25.9 <0.001

Notes: Mean ± SD. p≤ 0.05 values were considered statistically significant. Wilcoxon signed-rank test were used for comparison between baseline and final values.

Abbreviations: DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; SBP, systolic blood pressure; SD, standard deviation.